Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment
Leah J. Kershner, … , Jack F. Shern, Nancy Ratner
Leah J. Kershner, … , Jack F. Shern, Nancy Ratner
Published September 22, 2022
Citation Information: JCI Insight. 2022;7(18):e154513. https://doi.org/10.1172/jci.insight.154513.
View: Text | PDF
Research Article Cell biology Oncology

Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment

  • Text
  • PDF
Abstract

To define alterations early in tumor formation, we studied nerve tumors in neurofibromatosis 1 (NF1), a tumor predisposition syndrome. Affected individuals develop neurofibromas, benign tumors driven by NF1 loss in Schwann cells (SCs). By comparing normal nerve cells to plexiform neurofibroma (PN) cells using single-cell and bulk RNA sequencing, we identified changes in 5 SC populations, including a de novo SC progenitor–like (SCP-like) population. Long after Nf1 loss, SC populations developed PN-specific expression of Dcn, Postn, and Cd74, with sustained expression of the injury response gene Postn and showed dramatic expansion of immune and stromal cell populations; in corresponding human PNs, the immune and stromal cells comprised 90% of cells. Comparisons between injury-related and tumor monocytes/macrophages support early monocyte recruitment and aberrant macrophage differentiation. Cross-species analysis verified each SC population and unique conserved patterns of predicted cell-cell communication in each SC population. This analysis identified PROS1-AXL, FGF-FGFR, and MIF-CD74 and its effector pathway NF-κB as deregulated in NF1 SC populations, including SCP-like cells predicted to influence other types of SCs, stromal cells, and/or immune cells in mouse and human. These findings highlight remarkable changes in multiple types of SCs and identify therapeutic targets for PN.

Authors

Leah J. Kershner, Kwangmin Choi, Jianqiang Wu, Xiyuan Zhang, Melissa Perrino, Nathan Salomonis, Jack F. Shern, Nancy Ratner

×

Figure 6

CellPhoneDB analysis of predicted major SC-cell interactions in mouse and human PNs.

Options: View larger image (or click on image) Download as PowerPoint
CellPhoneDB analysis of predicted major SC-cell interactions in mouse an...
CIRCOS plots. (A) Immune cells, stromal cells, and SCs produce midkine (MDK) and pleiotrophin (PTN); these ligands act mainly via the phosphatase PTPRZ1 in SCP-like cells. (B) SCP-like cells and myelinating SCs are predicted to produce PROS1, a ligand for the AXL receptor; AXL is present on immune cells, stromal cells, and some SCs. (C) Myelinating SCs are predicted to produce FGF1 and FGF2, affecting largely stromal cells through the receptor FGFR1. Other SC types are also predicted to express FGF1. (D) SCP-like cells are predicted to produce the ligands APP and MIF, affecting immune cells via the CD74 receptor. M-SC, myelinating SC; NM-SC, nonmyelinating SC.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts